Overview

Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)

Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
This is a Canadian randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the clinical efficacy and safety of adalimumab versus placebo when used to treat subjects with a diagnosis of osteoarthritis of the knee, and with clinical features of inflammation, whose pain persists despite receiving maximum tolerated doses of conventional therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Research & Education in Arthritis
Collaborator:
AbbVie
Treatments:
Adalimumab